Intravacc, Primrose to advance conjugate vaccine development

"Intravacc and Primrose collaborate to advance conjugate vaccine development, marking a significant step in immunization innovation. This partnership aims to harness their respective expertise to drive progress in combating infectious diseases. Stay tuned for updates on their joint efforts towards vaccine advancement."

Contract development and manufacturing organisation (CDMO) Intravacc and biotechnology company Primrose Bio have announced a strategic collaboration aimed at bolstering the conjugate vaccine development and supply.

This collaboration is set to provide third parties with a comprehensive solution for vaccine conjugation, manufacturing, and supply, streamlining the process for developers.

Intravacc will provide its extensive technical capabilities, advanced facilities, and expertise in antigen conjugation process development, scale-up, and GMP production of conjugate vaccines.

This expertise is crucial in ensuring the quality and efficacy of vaccines as they progress from concept to commercialisation.

Intravacc CEO Dr Jan Groen said: “We are excited to announce our partnership with Primrose Bio. By combining our expertise with Primrose’s cutting-edge technologies, we aim to revolutionise the landscape of conjugate vaccine development, ultimately benefiting millions worldwide.”

Sourced from Pharmaceutical Technology